Researchers at the University of Utah’s Huntsman Cancer Institute discovered in laboratory studies that an experimental drug called selinexor may block a crucial survival pathway exploited by myelofibrosis cells. Their study was recently published in Clinical Cancer...
Myelofibrosis
Category
Sierra Oncology Obtains Regulatory Clarity with U.S. FDA on Phase 3 Trial Design of Momelotinib for Myelofibrosis
Sierra Oncology announced it has received clarity with the U.S. FDA concerning the design of a Phase 3 clinical trial for momelotinib intended to support potential registration for the treatment of patients with myelofibrosis previously treated with a JAK inhibitor. ...
Investigator Initiated Trial to Evaluate Myelofibrosis Treatment
Primary myelofibrosis (MF) is a relatively rare bone marrow cancer. It is currently classified as a myeloproliferative neoplasm, in which the proliferation of an abnormal clone of hematopoietic stem cells in the bone marrow and other sites results in fibrosis, or the...